MicroCATCH: Liquid-biopsy biomarkers for personalised neurology and interoperable health-data integration

BrainDTech is seeking partners for a joint interregional PRECISEU proposal focused on the clinical validation and implementation of MicroCATCH, its proprietary liquid-biopsy platform for neurological, neurodegenerative, and neuroinflammatory diseases. BrainDTech’s technology is based on the analysis of miRNA signatures from microglial microvesicles collected through liquid biopsy, with the goal of enabling earlier detection, more precise patient stratification, and longitudinal treatment monitoring in brain disorders. This approach is designed to generate clinically meaningful biomarker information through a minimally invasive and scalable diagnostic strategy.

The opportunity is well aligned with PRECISEU, which supports TRL 6–8 interregional projects in personalised medicine, with a focus on health data and digital health, real-world data, interoperability, and solutions that improve adoption and equity of access. BrainDTech aims to build a consortium able to move MicroCATCH toward multicentre validation and practical integration into regional innovation and healthcare ecosystems.

BrainDTech is particularly interested in connecting with:

• Hospitals, neurology centres, and clinical research sites able to contribute patient cohorts and clinical validation

• Biobanks and research institutions with access to well-characterised samples

• Digital-health and health-data partners working on interoperability, multimodal data integration, federated analysis, or real-world evidence

• Industrial, regulatory, and implementation partners able to support assay standardisation, deployment planning, and adoption pathways

The envisioned project would combine biomarker innovation with data-driven personalised medicine, creating a cross-regional use case that can support clinical decision-making, translational research, and future personalised therapeutic programmes. BrainDTech is open to collaboration as technology provider, biomarker lead, and co-developer of the overall project concept.